• Please log in or register to access this feature.

Research Paper

The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

  1. Girija Dasmahapatra1,
  2. Hiral Patel1,
  3. Paul Dent2,3,4,5,
  4. Richard I. Fisher6,
  5. Jonathan Friedberg6,
  6. Steven Grant1,3,4,5,*

Article first published online: 30 JAN 2013

DOI: 10.1111/bjh.12206

Issue

British Journal of Haematology

British Journal of Haematology

Volume 161, Issue 1, pages 43–56, April 2013

Additional Information

How to Cite

Dasmahapatra, G., Patel, H., Dent, P., Fisher, R. I., Friedberg, J. and Grant, S. (2013), The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. British Journal of Haematology, 161: 43–56. doi: 10.1111/bjh.12206

Author Information

  1. 1

    Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA

  2. 2

    Department of Neurosurgery, Virginia Commonwealth University, Richmond, VA, USA

  3. 3

    Department of Biochemistry, Virginia Commonwealth University, Richmond, VA, USA

  4. 4

    Department of Molecular and Human Genetics, Virginia Commonwealth University, Richmond, VA, USA

  5. 5

    Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA

  6. 6

    Division of Hematology Oncology, University of Rochester Medical Center and the James P. Wilmot Cancer Center, Rochester, NY, USA

* Correspondence: Dr. Steven Grant, Division of Hematology/Oncology, Virginia Commonwealth University, Room 234, Goodwin Research Building, 401 College Street, Richmond, VA 23298, USA.
E-mail: stgrant@vcu.edu

Publication History

  1. Issue published online: 15 MAR 2013
  2. Article first published online: 30 JAN 2013
  3. Manuscript Accepted: 19 NOV 2012
  4. Manuscript Received: 14 AUG 2012

Funded by

  • Lymphoma SPORE award. Grant Numbers: 1P50 CA130805, CA63753, CA93738, CA100866
  • National Institutes of Health
  • Multiple Myeloma Research Foundation, Myeloma Spore
  • Leukemia and Lymphoma Society of America. Grant Number: P50CA142509
  • V Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (547K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

View Full Article with Supporting Information (HTML) Get PDF (547K)